Serum Protein Markers in Clear Cell Renal Cell Carcinoma

• DOI: 10.52733/ikcs24-proc-or3
• Publication Date: 2025-04-29T17:32:11Z
• Authors: Laura Davis; Betty Wang; Mohit Sindhan; Amanda Nizam; Christopher Weight; Phillip Abbosh; Steven Campbell; Robert Abouassaly; Adam Calaway¹; Pedro Barata; Laura Bukavina

BACKGROUND Renal Cell Carcinoma (RCC) is one of the most frequently diagnosed malignancies, yet non-invasive biomarkers for early detection and prognosis in RCC remain scarce. This study aims to identify serum protein markers predictive clear cell (ccRCC) development prognostic survival outcomes. METHODS Using UK Biobank, a prospective cohort >500,000 individuals, we analyzed proteomic data from participants who developed ccRCC after collection (Group 2), those prior 1), controls 3). Proteomic measurements were performed using Olink Proximity Extension Assay (PEA). Cox proportional hazards regression models estimated hazard ratios (HRs) cancer risk survival, adjusting age, sex, BMI, smoking status, renal function. Kaplan-Meier analysis evaluated markers. RESULTS: Five proteins—HAVCR1, REN, INHBB, NCR3LG1, PGF—were significantly associated with future development. HAVCR1 exhibited strongest performance (HR 5.1, 95% CI: 3.6–7.3, p<0.001; AUC 0.8756). Among all patients ccRCC, NCR3LG1 2.6, 1.4–5.1, p<0.002), PGF 2.2, 1.3–3.8, p<0.001), GDF15 1.8, 1.1–2.8, p<0.02) reduced survival. CONCLUSION identifies as promising diagnostic biomarker detection, PGF, serving potential Further validation independent cohorts needed facilitate clinical translation into tools ccRCC. https://doi.org/10.52733/IKCS24-Proc-or3 KEYWORDS